Details of Drug

Drug General Information (ID: D0726)
Drug Name	Glecaprevir
Drug Type	Small molecule
Drug Synonymous	Glecaprevir; ABT-493; UNII-K6BUU8J72P; 1365970-03-1; K6BUU8J72P; A-1282576.0; 1365970-03-1 (free); ABT 493; (3aR,7S,10S,12R,21E,24aR)-7-tert-butyl-N-[(1R,2R)-2-(difluoromethyl)-1-{[(1-methylcyclopropyl)sulfonyl]carbamoyl}cyclopropyl]-20,20-difluoro-5,8-dioxo-2,3,3a,5,6,7,8,11,12,20,23,24a-dodecahydro-1H,10H-9,12-methanocyclopenta[18,19][1,10,17,3,6]trioxadiazacyclononadecino[11,12-b]quinoxaline-10-carboxamide; (3aR,7S,10S,12R,21E,24aR)-7-tert-butyl-N-{(1R,2R)-2(difluoromethyl)-1-[(1-methylcyclopropane-1-sulfonyl)carbamoyl]cyclopropyl}-20,20-difluoro5,8-dioxo-2,3,3a,5,6,7,8,11,12,20,23,24a-dodecahydro-1H,10H-9,12methanocyclopenta[18,19][1,10,17,3,6]trioxadiazacyclononadecino[11,12-b]quinoxaline-10carboxamide; Glecaprevir [USAN]; Maviret; (3aR,7S,10S,12R,21E,24aR)-7-tert-butyl-N-[(1R,2R)-2-(difluoromethyl)-1-{[(1-methylcyclopropyl)sulfonyl]carbamoyl}cyclop ropyl]-20,20-difluoro-5,8-dioxo-2,3,3a,5,6,7,8,11,12,20,23,24a-dodecahydro-1H,10H-9,12-methanocyclopenta[18,19][1,10,17, 3,6]trioxadiazacyclononadecino[11,12-b]quinoxaline-10-carboxamide; O31; ABT-493(Glecaprevir); Glecaprevir (USAN/INN); SCHEMBL883097; ABT493; CHEMBL3545363; GTPL11267; (1R,14E,18R,22R,26S,29S)-26-tert-butyl-N-[(1R,2R)-2-(difluoromethyl)-1-[(1-methylcyclopropyl)sulfonylcarbamoyl]cyclopropyl]-13,13-difluoro-24,27-dioxo-2,17,23-trioxa-4,11,25,28-tetrazapentacyclo[26.2.1.03,12.05,10.018,22]hentriaconta-3,5,7,9,11,14-hexaene-29-carboxamide; AMY38157; EX-A1940; s5720; CS-8098; DB13879; AC-33419; HY-17634; J3.646.120I; D10814; A-1282576; A-12825760; 3,6]trioxadiazacyclononadecino[11,12-b]quinoxaline-10-carboxamide; (3aR,7S,10S,12R,21E,24aR)-7-tert-butyl-N-((1R,2R)-2-(difluoromethyl)-1-((1-methylcyclopropane-1-sulfonyl)carbamoyl)cyclopropyl)-20,20-difluoro-5,8-dioxo-2,3,3a,5,6,7,8,11,12,20,23,24a-dodecahydro-1H,10H-9,12-methanocyclopenta(18,19)(1,10,17,3,6)trioxadiazacyclononadecino(11,12-b)quinoxaline-10-carboxamide; (3aR,7S,10S,12R,21E,24aR)-7-tert-butyl-N-[(1R,2R)-2-(difluoromethyl)-1-{[(1-methylcyclopropyl)sulfonyl]carbamoyl}cyclop; (3aR,7S,10S,12R,21E,24aR)-7-tert-butyl-N-{(1R,2R)-2- (difluoromethyl)-1-[(1-methylcyclopropane-1-sulfonyl)carbamoyl]cyclopropyl}-20,20-difluoro- 5,8-dioxo-2,3,3a,5,6,7,8,11,12,20,23,24a-dodecahydro-1H,10H-9,12- methanocyclopenta[18,19][1,10,17,3,6]trioxadiazacyclononadecino[11,12-b]quinoxaline-10- carboxamide hydrate; Cyclopropanecarboxamide, N-((((1R,2R)-2-((4,4-difluoro-4-(3-hydroxy-2-quinoxalinyl)-2-buten-1-yl)oxy)cyclopentyl)oxy)carbonyl)-3-methyl-L-valyl-(4R)-4-hydroxy-L-prolyl-1-amino-2-(difluoromethyl)-N-((1-methylcyclopropyl)sulfonyl)-, cyclic (1->2)-ether, (1R,2R)-; ropyl]-20,20-difluoro-5,8-dioxo-2,3,3a,5,6,7,8,11,12,20,23,24a-dodecahydro-1H,10H-9,12-methanocyclopenta[18,19][1,10,17, Click to Show/Hide
Therapeutic Class	Antiviral Agents
Structure
Structure	3D Structure		2D Structure
Formula	C38H46F4N6O9S
InChI	InChI=1S/C38H46F4N6O9S/c1-35(2,3)28-32(50)48-19-20(17-24(48)30(49)46-37(18-21(37)29(39)40)33(51)47-58(53,54)36(4)14-15-36)56-31-27(43-22-9-5-6-10-23(22)44-31)38(41,42)13-8-16-55-25-11-7-12-26(25)57-34(52)45-28/h5-6,8-10,13,20-21,24-26,28-29H,7,11-12,14-19H2,1-4H3,(H,45,52)(H,46,49)(H,47,51)/b13-8+/t20-,21+,24+,25-,26-,28-,37-/m1/s1
InChIKey	MLSQGNCUYAMAHD-ITNVBOSISA-N
Canonical SMILES	CC1(CC1)S(=O)(=O)NC(=O)[C@]2(C[C@H]2C(F)F)NC(=O)[C@@H]3C[C@@H]4CN3C(=O)[C@@H](NC(=O)O[C@@H]5CCC[C@H]5OC/C=C/C(C6=NC7=CC=CC=C7N=C6O4)(F)F)C(C)(C)C
External Link
	Pubchem ID	66828839
	INTEDE ID	DR1768
	VARIDT ID	DR01308

Drug-Drug Interaction Network
Sunburst Graph		Legend Information AM002 Affected cellular transport AM004 Affected intra/extra-hepatic metabolism AM006 Pharmacodynamic additive effects BM010 Transporter inhibition BM011 Transporter induction BM017 CYP450 enzyme inhibition BM019 UGT inhibition BM022 CYP450 enzyme induction BM109 Increased risk of other adverse reactions (Unspecific)
Relation Graph

Full list of drugs interacting with Glecaprevir
Affected cellular transport
	Transporter inhibition					Drug Num: 46
Drug ID		Drug Name	Formula	Pubchem ID	Severity Level		Interaction Detail	REF
D0116		Atazanavir	C38H52N6O7	148192	Major		Inter Info	[1], [2]
D0380		Colchicine	C22H25NO6	6167	Major		Inter Info	[7], [8], [9]
D0402		Cyclosporine	C62H111N11O12	5284373	Major		Inter Info	[10], [11], [1]
D0426		Darunavir	C27H37N3O7S	213039	Major		Inter Info	[1], [12]
D0551		Edoxaban	C24H30ClN7O4S	10280735	Major		Inter Info	[5], [13], [14]
D0171		Berotralstat	C30H26F4N6O	137528262	Major		Inter Info	[16], [17], [18]
D0956		Lovastatin	C24H36O5	53232	Major		Inter Info	[5], [1], [4]
D1232		Pazopanib	C21H23N7O2S	10113978	Major		Inter Info	[5], [19], [20]
D1329		Pravastatin	C23H36O7	54687	Major		Inter Info	[1]
D1388		Relugolix	C29H27F2N7O5S	10348973	Major		Inter Info	[21], [22]
D1430		Rosuvastatin	C22H28FN3O6S	446157	Major		Inter Info	[1]
D1688		Venetoclax	C45H50ClN7O7S	49846579	Major		Inter Info	[23], [5], [24]
D0038		Aliskiren	C30H53N3O6	5493444	Moderate		Inter Info	[25], [5], [26]
D0096		Apixaban	C25H25N5O4	10182969	Moderate		Inter Info	[5], [27]
D0155		Bempedoic acid	C19H36O5	10472693	Moderate		Inter Info	[1], [28], [29]
D0176		Betrixaban	C23H22ClN5O3	10275777	Moderate		Inter Info	[30]
D0182		Binimetinib	C17H15BrF2N4O3	10288191	Moderate		Inter Info	[23], [5], [31]
D0195		Bosutinib	C26H29Cl2N5O3	5328940	Moderate		Inter Info	[5], [32]
D0199		Brentuximab vedotin	NA	NA	Moderate		Inter Info	[33], [1]
D0375		Cobicistat	C40H53N7O5S2	25151504	Moderate		Inter Info	[1]
D0376		Cobimetinib	C21H21F3IN3O2	16222096	Moderate		Inter Info	[5], [34]
D0425		Darolutamide	C19H19ClN6O2	67171867	Moderate		Inter Info	[5], [1], [35]
D0429		Daunorubicin	C27H29NO10	30323	Moderate		Inter Info	[36], [37], [38]
D0430		Daunorubicin (liposomal)	C27H29NO10	30323	Moderate		Inter Info	[36], [37], [38]
D0491		Digoxin	C41H64O14	2724385	Moderate		Inter Info	[39], [1]
D0568		Enasidenib	C19H17F6N7O	89683805	Moderate		Inter Info	[23], [40], [1]
D0577		Entrectinib	C31H34F2N6O2	25141092	Moderate		Inter Info	[23], [5], [41]
D0629		Everolimus	C53H83NO14	6442177	Moderate		Inter Info	[42]
D0686		Fluvastatin	C24H26FNO4	446155	Moderate		Inter Info	[1]
D0720		Gilteritinib	C29H44N8O3	49803313	Moderate		Inter Info	[5], [43]
D0896		Larotrectinib	C21H22F2N6O2	46188928	Moderate		Inter Info	[23], [5], [44]
D1409		Ripretinib	C24H21BrFN5O2	71584930	Moderate		Inter Info	[23], [45]
D1663		Ubrogepant	C29H26F3N5O3	68748835	Moderate		Inter Info	[1], [46]
D0788		Idarubicin	C26H27NO9	42890	Moderate		Inter Info	[36], [37], [38]
D0789		Idelalisib	C22H18FN7O	11625818	Moderate		Inter Info	[47], [48]
D0867		Itraconazole	C35H38Cl2N8O4	55283	Moderate		Inter Info	[23], [5], [49]
D0899		Lefamulin	C28H45NO5S	25185057	Moderate		Inter Info	[1], [50]
D0963		Lusutrombopag	C29H32Cl2N2O5S	49843517	Moderate		Inter Info	[51]
D0980		Maraviroc	C29H41F2N5O	3002977	Moderate		Inter Info	[52]
D1101		Naldemedine	C32H34N4O6	54732242	Moderate		Inter Info	[5], [53]
D1301		Pitavastatin	C25H24FNO4	5282452	Moderate		Inter Info	[1]
D1396		Revefenacin	C35H43N5O4	11753673	Moderate		Inter Info	[28], [29], [54]
D1532		Talazoparib	C19H14F2N6O	135565082	Moderate		Inter Info	[57]
D0658		Fidaxomicin	C52H74Cl2O18	10034073	Minor		Inter Info	[23], [5], [59]
D0797		Indacaterol	C24H28N2O3	6918554	Minor		Inter Info	[60]
D1104		Naloxegol	C34H53NO11	56959087	Minor		Inter Info	[61]
	Transporter induction					Drug Num: 1
Drug ID		Drug Name	Formula	Pubchem ID	Severity Level		Interaction Detail	REF
D1592		Tipranavir	C31H33F3N2O5S	54682461	Moderate		Inter Info	[1]
Affected intra/extra-hepatic metabolism
	CYP450 enzyme inhibition					Drug Num: 5
Drug ID		Drug Name	Formula	Pubchem ID	Severity Level		Interaction Detail	REF
D0120		Atorvastatin	C33H35FN2O5	60823	Major		Inter Info	[3], [1], [4]
D1473		Simvastatin	C25H38O5	54454	Major		Inter Info	[3], [1], [4]
D1476		Sirolimus	C51H79NO13	5284616	Moderate		Inter Info	[23], [55], [56]
D1526		Tacrolimus	C44H69NO12	445643	Moderate		Inter Info	[23], [55], [56]
D1549		Temsirolimus	C56H87NO16	6918289	Moderate		Inter Info	[58]
	CYP450 enzyme induction					Drug Num: 47
Drug ID		Drug Name	Formula	Pubchem ID	Severity Level		Interaction Detail	REF
D0255		Carbamazepine	C15H12N2O	2554	Major		Inter Info	[5], [6], [1]
D0554		Efavirenz	C14H9ClF3NO2	64139	Major		Inter Info	[5], [6], [1]
D1265		Phenobarbital	C12H12N2O3	4763	Major		Inter Info	[5], [6], [1]
D1283		Phenytoin	C15H12N2O2	1775	Major		Inter Info	[5], [6], [1]
D1340		Primidone	C12H14N2O2	4909	Major		Inter Info	[5], [6], [1]
D1400		Rifampicin	C43H58N4O12	135398735	Major		Inter Info	[1]
D1502		St. John's Wort	NA	NA	Major		Inter Info	[5], [6], [1]
D0061		Aminoglutethimide	C13H16N2O2	2145	Moderate		Inter Info	[1]
D0071		Amobarbital	C11H18N2O3	2164	Moderate		Inter Info	[1]
D0095		Apalutamide	C21H15F4N5O2S	24872560	Moderate		Inter Info	[1]
D0106		Armodafinil	C15H15NO2S	9690109	Moderate		Inter Info	[1]
D0178		Bexarotene	C24H28O2	82146	Moderate		Inter Info	[1]
D0194		Bosentan	C27H29N5O6S	104865	Moderate		Inter Info	[1]
D0204		Brigatinib	C29H39ClN7O2P	68165256	Moderate		Inter Info	[1]
D0224		Butabarbital	C10H16N2O3	2479	Moderate		Inter Info	[1]
D0225		Butalbital	C11H16N2O3	2481	Moderate		Inter Info	[1]
D0300		Cenobamate	C10H10ClN5O2	11962412	Moderate		Inter Info	[1]
D0432		Deferasirox	C21H15N3O4	214348	Moderate		Inter Info	[1]
D0453		Dexamethasone	C22H29FO5	5743	Moderate		Inter Info	[1]
D0555		Elagolix	C32H30F5N3O5	11250647	Moderate		Inter Info	[1]
D0578		Enzalutamide	C21H16F4N4O2S	15951529	Moderate		Inter Info	[1]
D0628		Etravirine	C20H15BrN6O	193962	Moderate		Inter Info	[1]
D0639		Felbamate	C11H14N2O4	3331	Moderate		Inter Info	[1]
D0697		Fosphenytoin	C16H15N2O6P	56339	Moderate		Inter Info	[1]
D0601		Eslicarbazepine	C15H14N2O2	9881504	Moderate		Inter Info	[1]
D0872		Ivosidenib	C28H22ClF3N6O3	71657455	Moderate		Inter Info	[1]
D0741		Griseofulvin	C17H17ClO6	441140	Moderate		Inter Info	[1]
D0901		Lemborexant	C22H20F2N4O2	56944144	Moderate		Inter Info	[1]
D0905		Lesinurad	C17H14BrN3O2S	53465279	Moderate		Inter Info	[1]
D0953		Lorlatinib	C21H19FN6O2	71731823	Moderate		Inter Info	[1]
D1040		Methylphenobarbital	C13H14N2O3	8271	Moderate		Inter Info	[1]
D1078		Mitotane	C14H10Cl4	4211	Moderate		Inter Info	[1]
D1099		Nafcillin	C21H22N2O5S	8982	Moderate		Inter Info	[1]
D1128		Nevirapine	C15H14N4O	4463	Moderate		Inter Info	[1]
D1186		Oritavancin	C86H97Cl3N10O26	16136912	Moderate		Inter Info	[1]
D1190		Osimertinib	C28H33N7O2	71496458	Moderate		Inter Info	[1]
D1198		Oxcarbazepine	C15H12N2O2	34312	Moderate		Inter Info	[1]
D1248		Pentobarbital	C11H18N2O3	4737	Moderate		Inter Info	[1]
D1258		Pexidartinib	C20H15ClF3N5	25151352	Moderate		Inter Info	[1]
D1274		Phenylbutazone	C19H20N2O2	4781	Moderate		Inter Info	[1]
D1399		Rifabutin	C46H62N4O11	135398743	Moderate		Inter Info	[1]
D1401		Rifapentine	C47H64N4O12	135403821	Moderate		Inter Info	[1]
D1433		Rufinamide	C10H8F2N4O	129228	Moderate		Inter Info	[1]
D1453		Secobarbital	C12H18N2O3	5193	Moderate		Inter Info	[1]
D1518		Sulfinpyrazone	C23H20N2O3S	5342	Moderate		Inter Info	[1]
D1652		Troglitazone	C24H27NO5S	5591	Moderate		Inter Info	[1]
D1687		Vemurafenib	C23H18ClF2N3O3S	42611257	Moderate		Inter Info	[1]
Pharmacodynamic additive effects
	Increased risk of other adverse reactions (Unspecific)					Drug Num: 1
Drug ID		Drug Name	Formula	Pubchem ID	Severity Level		Interaction Detail	REF
D0619		Ethinylestradiol	C20H24O2	5991	Major		Inter Info	[1], [15]

References
1	Product Information. Mavyret (glecaprevir-pibrentasvir). Abbott Pharmaceutical, Abbott Park, IL.
2	Product Information. Reyataz (atazanavir). Bristol-Myers Squibb, Princeton, NJ.
3	Neuvonen PJ, Backman JT, Niemi M "Pharmacokinetic comparison of the potential over-the-counter statins simvastatin, lovastatin, fluvastatin and pravastatin." Clin Pharmacokinet 47 (2008): 463-74. [PMID: 18563955]
4	Richter WO, Jacob BG, Schwandt P "Interaction between fibre and lovastatin." Lancet 338 (1991): 706. [PMID: 1679514]
5	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
6	Patel S, Robinson R, Burk M "Hypertensive crisis associated with St. John's Wort." Am J Med 112 (2002): 507-8. [PMID: 11959071]
7	Garrouste C, Philipponnet C, Kaysi S, Enache I, Tiple A, Heng AE "Severe colchicine intoxication in a renal transplant recipient on cyclosporine." Transplant Proc 44 (2012): 2851-2. [PMID: 23146540]
8	Jonsson J, Gelpi JR, Light JA, Aquino A, Maszaros S "Colchicine-induced myoneuropathy in a renal transplant patient." Transplantation 53 (1992): 1369-71. [PMID: 1604496]
9	Kuncl RW, Duncan G, Watson D, et al "Colchicine myopathy and neuropathy." N Engl J Med 316 (1987): 1562-8. [PMID: 3035372]
10	Ducharme MP, Warbasse LH, Edwards DJ "Disposition of intravenous and oral cyclosporine after administration with grapefruit juice." Clin Pharmacol Ther 57 (1995): 485-91. [PMID: 7768070]
11	Hollander AAMJ, Vanrooij J, Lentjes EGWM, Arbouw F, Vanbree JB, Schoemaker RC, Vanes LA, Vanderwoude FJ, Cohen AF "The effect of grapefruit juice on cyclosporine and prednisone metabolism in transplant patients." Clin Pharmacol Ther 57 (1995): 318-24. [PMID: 7697949]
12	Product Information. Prezista (darunavir). Ortho Biotech Inc, Bridgewater, NJ.
13	Mendell J, Zahir H, Matsushima N, et al. "Drug-Drug Interaction Studies of Cardiovascular Drugs Involving P-Glycoprotein, an Efflux Transporter, on the Pharmacokinetics of Edoxaban, an Oral Factor Xa Inhibitor." Am J Cardiovasc Drugs (2013):. [PMID: 23784266]
14	Product Information. Savaysa (edoxaban). Daiichi Sankyo, Inc., Parsippany, NJ.
15	Schubert W, Eriksson U, Edgar B, Cullberg G, Hedner T "Flavonoids in grapefruit juice inhibit the in vitro hepatic metabolism of 17B-estradiol." Eur J Drug Metab Pharmacokinet 20 (1995): 219-24. [PMID: 8751044]
16	Ace LN, Jaffe JM, Kunka RL "Effect of food and an antacid on quinidine bioavailability." Biopharm Drug Dispos 4 (1983): 183-90. [PMID: 6882885]
17	Min DI, Ku YM, Geraets DR, Lee HC "Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers." J Clin Pharmacol 36 (1996): 469-76. [PMID: 8739026]
18	Product Information. Orladeyo (berotralstat). BioCryst Pharmaceuticals Inc, Durham, NC.
19	Product Information. Votrient (pazopanib). GlaxoSmithKline, Research Triangle Park, NC.
20	Tan AR, Gibbon DG, Stein MN, et al. "Effects of ketoconazole and esomeprazole on the pharmacokinetics of pazopanib in patients with solid tumors." Cancer Chemother Pharmacol 71 (2013): 1635-43. [PMID: 23636448]
21	Product Information. Juxtapid (lomitapide). Aegerion Pharmaceuticals Inc, Cambridge, MA.
22	Product Information. Orgovyx (relugolix). Myovant Sciences, Inc., Brisbane, CA.
23	Cerner Multum, Inc. "Australian Product Information.".
24	Product Information. Venclexta (venetoclax). AbbVie US LLC, North Chicago, IL.
25	Canadian Pharmacists Association.
26	Tapaninen T, Backman JT, Kurkinen K, Neuvonen P, Niemi M "Itraconazole, a P-glycoprotein and CYP3A4 inhibitor, markedly raises the plasma concentrations and enhances the renin-inhibiting effect of aliskiren." J Clin Pharmacol 51 (2011): 359-67. [PMID: 20400651]
27	Product Information. Eliquis (apixaban). Bristol-Myers Squibb Canada Inc, Montreal, IN.
28	Product Information. Nexletol (bempedoic acid). Esperion Therapeutics, Ann Arbor, MI.
29	Product Information. Nexlizet (bempedoic acid-ezetimibe). Esperion Therapeutics, Ann Arbor, MI.
30	Product Information. Bevyxxa (betrixaban). Portola Pharmaceuticals, South San Francisco, CA.
31	Product Information. Mektovi (binimetinib). Array BioPharma Inc., Boulder, CO.
32	Product Information. Bosulif (bosutinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
33	Product Information. Adcetris (brentuximab vedotin). Seattle Genetics Inc, Bothell, WA.
34	Product Information. Cotellic (cobimetinib). Genentech, South San Francisco, CA.
35	Product Information. Nubeqa (darolutamide). Bayer HealthCare Pharmaceuticals Inc., Whippany, NJ.
36	Multum Information Services, Inc. Expert Review Panel.
37	Product Information. Daunoxome (daunorubicin liposomal). Nexstar Pharmaceuticals Inc, Boulder, CO.
38	Product Information. Idamycin (idarubicin). Pharmacia and Upjohn, Kalamazoo, MI.
39	Darcy PF "Nutrient-drug interactions." Adverse Drug React Toxicol Rev 14 (1995): 233-54. [PMID: 8845456]
40	Product Information. Idhifa (enasidenib). Celgene Corporation, Summit, NJ.
41	Product Information. Rozlytrek (entrectinib). Genentech, South San Francisco, CA.
42	Product Information. Afinitor (everolimus). Novartis Pharmaceuticals, East Hanover, NJ.
43	Product Information. Xospata (gilteritinib). Astellas Pharma US, Inc, Deerfield, IL.
44	Product Information. Vitrakvi (larotrectinib). Bayer Pharmaceutical Inc, West Haven, CT.
45	Product Information. Qinlock (ripretinib). Deciphera Pharmaceuticals, Waltham, MA.
46	Product Information. Ubrelvy (ubrogepant). Allergan Inc, Irvine, CA.
47	Product Information. Incivek (telaprevir). Vertex Pharmaceuticals, Cambridge, MA.
48	Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA.
49	Product Information. Sporanox (itraconazole). Janssen Pharmaceutica, Titusville, NJ.
50	Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
51	EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring.".
52	Product Information. Selzentry (maraviroc). Pfizer U.S. Pharmaceuticals Group, New York, NY.
53	Product Information. Symproic (naldemedine). Shionogi USA Inc, Florham Park, NJ.
54	Product Information. Yupelri (revefenacin). Mylan Specialty, Morgantown, WV.
55	Christians U, Schmidt G, Bader A, et al "Identification of drugs inhibiting the in vitro metabolism of tacrolimus by human liver microsomes." Br J Clin Pharmacol 41 (1996): 187-90. [PMID: 8866917]
56	Product Information. Parlodel (bromocriptine). Sandoz Pharmaceuticals Corporation, East Hanover, NJ.
57	Product Information. Talzenna (talazoparib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
58	Product Information. Torisel (temsirolimus). Wyeth-Ayerst Laboratories, Philadelphia, PA.
59	Product Information. Dificid (fidaxomicin). Optimer Pharmaceuticals, San Diego, CA.
60	Product Information. Arcapta Neohaler (indacaterol). Novartis Pharmaceuticals, East Hanover, NJ.
61	Product Information. Movantik (naloxegol). Astra-Zeneca Pharmaceuticals, Wilmington, DE.

Details of Drug

Details of Drug

Cite MecDDI

About MecDDI

Correspondence